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ABSTRACT
Transthyretin (TTR)-related amyloidosis (ATTR)
is a devastating disease which affects a
combination of organs including the heart and
the peripheral nerves, and which has a fatal
outcome if not treated within a average of
10 years. Tafamidis, or 2-(3,5-dichloro-phenyl)-
benzoxazole-6-carboxylic acid, selectively binds
to TTR with negative cooperativity and
kinetically stabilizes wild-type native TTR and
mutant TTR; tafamidis therefore has the
potential to halt the amyloidogenic cascade
initiated by TTR tetramer dissociation,
monomer misfolding, and aggregation. The
first tafamidis trial, Fx-005, evaluated the
effect of 18 months of tafamidis treatment
(20 mg once daily) on disease progression, as
well as assessing its safety in TTR-FAP Val30Met
patients. The secondary objective of this trial
was to study the pharmacodynamic
stabilization of mutated TTR. Tafamidis proved
effective in reducing the progress of
neuropathy, and in maintaining the
nutritional status and quality of life of stage 1
(able to walk without support) Val3OMet TTR-
FAP patients. Furthermore, TTR stabilization
was achieved in more than 90% of patients.
An extension study, Fx-006, was conducted to
determine the long-term safety and tolerability
of tafamidis and to assess the efficacy of the
drug on slowing disease progression. No
significant safety or tolerability issues were
noticed. Taken together, the results from both
trials indicated that the beneficial effects of
tafamidis were sustained over a 30-month
period and that starting treatment early is
desirable. Results are expected from an
extended open-label study but data that have
already been presented show that long-term use
of tafamidis in Val30Met patients is associated
with reduced progression in polyneuropathy.
Tafamidis was initially approved for commercial
use in Europe in 2011 and has since been
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approved for use in Japan, Mexico, and
Argentina where it is used as a first-line
treatment option for patients with early-stage
TTR-FAP. Patients should be carefully followed
at referral centers to ascertain the individual
response to treatment. In cases of
discontinuation, liver transplantation and
enrollment in clinical trials of novel drugs
aimed mostly toward suppression of TTR
production are options.
Keywords: Amyloidosis; Familial amyloid
polyneuropathy; Tafamidis; Transthyretin
INTRODUCTION
Transthyretin familial amyloid polyneuropathy
(TTR-FAP) is a devastating disease which not
only robs patients of their quality of life
(QOL)—mainly from nerve and heart
dysfunction—but also promises to inflict a
similar fate on their children [1, 2]. An
effective treatment for TTR-FAP is sorely
needed. There are currently two therapeutic
approaches which have proven effective in the
treatment of TTR-FAP caused by either
abnormal or dysfunctional proteins: One is to
interrupt the pathways through which TTR
causes TTR-FAP’s pathology; the other is to
eliminate (or at least decrease) the production
of the protein which leads to amyloid fibril
formation.
The first therapeutic approach to be tested
for TTR-FAP was liver transplantation (LT). This
eliminated the production of the causative TTR
mutant by the liver [3]. Although this therapy
has met with success, it is often limited as a
result of continued amyloid fibril formation
from wild-type (WT) TTR which results in
disease progression in some patients, even
though 98% of mutated TTR is no more
produced. The need for other therapeutic
approaches was therefore apparent.
The idea of altering the pathway of TTR to
amyloid fibril formation was conceived from
the in vitro observation that mutations in the
TTR protein destabilized its tetrameric structure
and enhanced amyloid fibril formation [4, 5]. If
this destabilization was a factor in amyloid
pathogenesis, therapeutic agents which
stabilized the structure of TTR might therefore
interfere with amyloid formation. Further
studies revealed that the binding of thyroxine
to TTR resulted in the stabilization of TTR in
solution [4, 5]. This led to a search for nontoxic,
small organic compounds which could bind to
the TTR–thyroxine-binding pocket and, hence,
stabilize TTR’s structure. Diflunisal, an
anti-inflammatory drug marketed for
treatment of arthritis, was shown to do this
[6], and this led to further studies to find safe
synthetic compounds that would selectively
stabilize TTR and that had greater
TTR-stabilizing potency.
THE DISCOVERY OF TAFAMIDIS
AS A POTENTIAL TREATMENT
FOR TTR-FAP
As mentioned above, mutations in TTR
destabilize its homotetrameric structure, and
lead to its dissociation into monomers that
misfold and misassemble into tissues as amyloid
deposits [4, 5]. Amyloidogenesis is certainly
responsible for neurodegeneration in TTR-FAP
[7–10, 41].
An in vitro analysis of material from patients
of Portuguese descent who inherited one copy
of the Val30Met TTR gene, with the presence of
a second mutation—namely T119 M—on their
second allele, showed that this resulted in the
formation of T119 M/Val30Met TTR
heterotetramers [4, 5, 11, 12]. These are more
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stable than the heterotetramers which comprise
the Val30Met and WT subunits, and the more
stable they are the less likely it is that they will
dissociate into the monomers that aggregate as
amyloid fibrils and cause toxicity to tissues [5].
This mechanism is known to ameliorate the
phenotypical expression of TTR-FAP [4, 5].
Based on this concept, a compound that could
selectively bind to the TTR tetrameric structure
and increase the kinetic barrier for tetramer
dissociation similar to the heterozygous
compound T119 M/Val30Met TTR was
searched for [4].
Of the multiple TTR kinetic stabilizers
reported, benzoxazoles were pursued to
identify an oral candidate exhibiting potent
and selective TTR binding in blood, while
lacking the nonsteroidal anti-inflammatory
activity that would be deleterious to patients
with cardiomyopathy (CM). Tafamidis, or 2-
(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic
acid, was the compound chosen for clinical
development. Tafamidis selectively binds TTR
with negative cooperativity and kinetically
stabilizes WT TTR and mutant TTR under fibril-
promoting conditions (at pH 4.5), denaturing
conditions (high urea concentration), and
physiological conditions, and therefore has the
potential to halt the amyloidogenic cascade
initiated by tetramer dissociation, monomer
misfolding, and aggregation [4]. A study by
Bulawa et al. [5] showed that tafamidis was able
to stabilize the two most significant mutations,
Val30Met and V122I TTR, in the same way as it
stabilized WT TTR. In addition, 30 other
amyloidogenic variants of TTR were stabilized
by tafamidis. Tafamidis dose-dependently
decreases the rate of tetramer dissociation at
physiological pH [4, 5]. Tafamidis binds with
high affinity to TTR at its T4-binding sites, and
there is no concern of thyroid metabolic effects
since less than 1% of TTR in circulating plasma
carries thyroxine [4, 5]. The primary carrier of
thyroxine is thyroxine-binding globulin. Of
note, tafamidis also binds selectively to TTR in
human plasma [4, 5].
Amyloid non-fibril intermediates can also
cause toxicity [4]. Therefore, for optimal
treatment, it is desired that the amyloidogenic
cascade is halted at the beginning—that is, the
rate-limiting step of the cascade that is
considered to be the dissociation of tetramers
into monomers (Fig. 1). For the development of
clinical trials on tafamidis, it was hypothesized
that TTR stabilization would lead to reduced
amyloid deposition and hence less
neurodegeneration (Fig. 2) [5].
CLINICAL TRIALS WITH TAFAMIDIS
Fx-005
The primary objective of the first tafamidis trial,
Fx-005, was to evaluate the effect of 18 months
of tafamidis treatment (20 mg once daily) on
disease progression, and to assess its safety in
TTR-FAP Val30Met patients [13]. The secondary
objective was to study the pharmacodynamic
stabilization of mutated TTR. This was a
multicenter, international, randomized,
placebo-controlled, double-blind trial. Patients
with stage 1 TTR-FAP (able to walk without
support) with autonomic or sensory–motor
neuropathies were enrolled at eight sites from
countries in Europe and South America
(Table 1). Patients from both sexes, aged
18–75 years, with confirmed amyloid-positive
biopsies, Karnofsky functional status C50, with
no other cause of neuropathy, no major liver or
kidney dysfunction, no prior LT, and New York
Heart Association (NYHA) status B3 were
enrolled. The following outcome measures
(validated for diabetic neuropathy were used
in the absence of any validated measure for
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TTR-FAP) were used: the neuropathy
impairment score in the lower limbs (NIS-LL),
which measures motor, sensory, and reflex
functions; the Norfolk quality of life-diabetic
neuropathy questionnaire (Norfolk QOL-DN),
which evaluates several aspects related to
sensory and motor neuropathy, as well as
autonomic dysfunction reflex on daily
activities; modified body mass index (mBMI),
which measures autonomic and gastrointestinal
function wasting; and summated scores from
multiple measures of nerve conduction,
quantitative sensory test, and heart rate
response to deep breath (HRDB). The
summated 7 nerve tests (
P
7 NTs) assess the
large-fiber function of nerves and summated 3
nerve tests (
P
3 NTs) assess the small-fiber
function of peripheral nerves [14, 15]. TTR
stabilization immunoturbidimetric assays were
performed on the plasma of patients [13].
The primary efficacy endpoints analyzed in
the intent-to-treat (ITT; all randomized patients)
population were the NIS-LL response to
treatment and least-square (LS) mean change
from baseline in Norfolk QOL-DN at 18 months.
Responders were considered as those who had
an increase in NIS-LL from baseline of\2 points.
Patients who discontinued due to LT were
defined as nonresponders [13].
A further analysis was performed in the
population that completed the study. The
efficacy-evaluable (EE) population was
Fig. 1 The amyloidogenic cascade is initiated by tetramer dissociation into monomers that misfold and aggregate causing
toxicity. The site of binding of tafamidis is marked. Transthyretin (TTR). Source: with permission from Ref. [5]
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Fig. 2 Mechanism of action of tafamidis binding to thyroxin-binding sites at the transthyretin tetramer preventing
dissociation into misfolded monomers and formation of ﬁbrils and amyloid. a Tafamidis prevents dissociation into
misfolded monomers and formation of amyloid ﬁbrils. b Amyloid deposits in peripheral nerves in different tissue stainings
(H&E, Gomori trichrome and Congo red)
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prespecified assuming a dropout of patients for
LT, as many of them were on its waiting list. As
secondary endpoints, change from baseline at
months 6, 12, and 18 in NIS-LL, Norfolk
QOL-DN,
P
7 NTs,
P
3 NTs, and mBMI were
used. Overall, 128 patients were randomized,
with 69% on the waiting list for LT. From this
population, 21% in each treatment arm (active
drug or placebo) discontinued to undergo LT.
Baseline characteristics of the patients receiving
either tafamidis or placebo were similar.
Patients were in the early stage of the disease
with greater involvement of small-fiber
function, in relatively good nutritional status,
and had some impairment of QOL [13].
In the ITT population, there was a trend
toward more NIS-LL responders in the tafamidis
group when compared with the placebo group
at month 18 (45.3% vs. 29.5%, respectively).
The change from baseline in Norfolk QOL-DN
score in the two groups was not significant at
month 18. In the EE population, significantly
more patients treated with tafamidis were
NIS-LL responders when compared to the
placebo-treated group (60% vs. 38.1%,
respectively, P = 0.041) and a significantly
lower LS mean change from baseline in
Norfolk QOL-DN in the tafamidis group when
compared to the placebo group was observed
(0.1 vs. 8.9 points, respectively, P = 0.045) [13].
In the analyses of the secondary endpoints in
the ITT population at 6, 12, and 18 months,
patients receiving tafamidis showed 52 % less
neurologic deterioration in NIS-LL when
compared to placebo-treated patients. This
difference was due to significantly more
weakness in distal lower limbs of the placebo
group. Nerve function measured by summated
scores were also analyzed in a 6-month interval
and showed 5 times greater mean deterioration
in small-fiber function (
P
3 NTs normal deviates
[nds]; P = 0.05) for the placebo group and no
trend toward more deterioration of large-fiber
function (
P
7 NTs nds; P = 0.066). mBMI
significantly increased from baseline at
18 months (LS mean ?39.3) compared to a
worsening in patients under placebo (-33.8).
Norfolk QOL-DN showed no trend toward
preservation of QOL in the tafamidis group
(P = 0.209). TTR stabilization was demonstrated
in 98% of patients treated with tafamidis.
Adverse events were equally distributed in
both treatment groups and were mostly
related to the disease itself [13].
The Fx-005 trial was a substantial challenge
due to the rarity of the disease, its systemic
nature, the absence of studies on its natural
course, and the fact that there were no devoted
validated outcome measures for TTR-FAP. There
was also a higher than anticipated dropout rate
due to LT (21% observed vs. 10% estimated).
The choice to undergo LT was equally
distributed in both treatment arms and
probably reflects the fact that patients had
been on the waiting list for LT for a long time
and could therefore not afford to wait until the
end of the study to make their decision when
they were called for LT. Furthermore, LT was
considered the standard of care at that time the
study was conducted and so patients had a
difficult decision on whether to continue using
an experimental drug or to undergo LT.
The choice to consider patients who
underwent LT as nonresponders possibly
influenced the analyses of NIS-LL in the ITT
population, probably underpowering the effect
on NIS-LL progression. In spite of the inability
to demonstrate statistical significance in the
primary outcomes, overall the results
demonstrated the potential of tafamidis to
slow neurologic deterioration and maintain
nutritional status. Tafamidis was well tolerated
which is important for a continuous-use drug
[13]. Future studies would be necessary to study
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the long-term effects of tafamidis on disease
progression.
Fx-006
The extension study, Fx-006, was conducted to
determine the long-term safety and tolerability
of tafamidis, and to assess its efficacy on slowing
disease progression [16]. Patients with TTR-FAP
who completed the previous study [13] were
eligible to enter this open-label, multicenter,
international, single-arm trial in which all
patients received tafamidis (20 mg once daily)
for 12 months. Patients who were randomized
Table 1 Summary of tafamidis trials
Protocol Design Number of
participants
Primary
endpoints
AEs Outcomes
Fx-005
[13]
Phase II/III,
randomized-
controlled,
double-blind trial
Treatment: placebo
or tafamidis 20 mg
once daily for
18 months
128 Val30Met
TTR
mutation
proved
patients
NIS-LL,
Norfolk
QOL-DN
Same incidence of AEs and
SAEs in both treatment
arms; urinary infection and
diarrhea more frequent in
the placebo group
EE population NIS-LL
responders: 60% in tafamidis
group, 38.1% in placebo group
(P = 0.041); EE TQoL change
from baseline: 0.1 in tafamidis
group, 8.9 in placebo group
(P = 0.045)
Fx-006
[16]
Single-arm, open-
label extension of
Fx-005 to evaluate
safety and efﬁcacy
of tafamidis
Treatment: tafamidis
20 mg once daily
for 12 months
86 Val30Met
TTR
mutation
proved
patients
NIS-LL,
Norfolk
QOL-DN
No new safety signs Beneﬁcial effects of tafamidis
were sustained over a
30-month period with gradual
NIS-LL increase to month 30;
early-start treatment is
desirable
FX1A-
201
[17]
Multicenter, open-
label trial
Treatment: tafamidis
20 mg once daily
for 12 months
21 TTR
mutation
patients
excluding
Val30Met
and
Val122Ile
TTR
stabilization
at week 6
Most common AEs: falls
(24%), diarrhea (24%), and
extremity pain (19%)
TTR stabilization at week 6 was
achieved in 18 (94.7%) of 19
patients in the ITT population
FX1B-
201
[21]
Phase II, open-label
trial
Treatment: tafamidis
20 mg once daily
for 12 months
with routine
standard of care
31 wild-type
CM patients
and 4 TTR
V122I CM
patients
TTR
stabilization
at week 6
Well tolerated;
7 of 31 wild-type CM patients
had bouts of diarrhea
96.8% achieved TTR
stabilization after 6 weeks;
Kaplan–Meier analysis of
survival from time of diagnosis
was 87.5% at 30 months;
25.7% experienced at least one
cardiovascular-related
hospitalization; 25.7%
experienced the composite
endpoint of death or
cardiovascular-related
hospitalization; NYHA was
improved or preserved for 75%
of patients after 12 months
AEs adverse events, CM cardiomyopathy, EE efﬁcacy evaluable, NIS-LL neuropathy impairment score in the lower limbs, Norfolk
QOL-DN Norfolk quality of life-diabetic neuropathy questionnaire, NYHA New York heart association, SAEs serious adverse events,
TTR transthyretin, TQoL quality of life
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to the placebo arm in the previous study were
switched to the active drug arm and constituted
the placebo-tafamidis group; patients who were
on tafamidis in the previous study were
continued on tafamidis and constituted the
tafamidis-tafamidis group. Values obtained at
the 18-month visit of the previous study were
considered as baseline values for the extension
study, except for 14 patients who went off-drug
for a period for more than 2 months due to
delays in regulatory approval at their sites. For
these patients, new baseline values were
obtained and they were not included in the
ITT population [16].
Efficacy measures were the same as for the
previous study [13–15] and were conducted
every 6 months on the ITT population [16].
Adverse events were monitored for the duration
of the study. Additional safety measures
included 12-lead electrocardiogram (EKG),
Holter monitoring, laboratory tests, vital signs,
physical examination, ophthalmologic
evaluation with fundal photography, and
echocardiogram. TTR stabilization was
continuously measured by an
immunoturbidimetric validated assay [13, 16].
To assess efficacy, three hypotheses were
proposed. First, that the effect of tafamidis to
slow disease progression could be sustained for
additional 12 months. To analyze this, the
monthly rate of change during the first
18 months was compared to the monthly rate
of change during the extension period of the
study for the tafamidis-tafamidis population.
Second, that tafamidis given to patients who
were on placebo in Fx-005 [13] could slow
disease progression. To evaluate this, the
monthly rate of change of several outcomes
was compared during Fx-006 and Fx-005 in the
placebo-tafamidis group. Finally, that earlier
treatment with tafamidis resulted in better
outcomes. Changes in several efficacy
measures from the baseline of Fx-005 [13] with
month 12 of Fx-006 were compared in the
tafamidis-tafamidis group and in the placebo-
tafamidis group. Muscle weakness at the
individual joint locations was also evaluated
for early-start treatment effect [16].
From the 91 patients who completed Fx-005
study [13], 86 (94.5%) were enrolled in Fx-006
[16]. Five patients decided not to participate in
the extension phase. Of the 86 patients that
were enrolled, 71 were considered as the ITT
population since 14 (16.3 %) were excluded due
to an interruption in treatment of more than
2 months between the studies and one other
who did not receive tafamidis. Sixty-three
(88.7%) completed the extension study. The
demographic characteristics of both groups
were similar, although patients from the
placebo-tafamidis arm presented greater
disease severity as could be noticed by their
NIS-LL values and other parameters at the start
of the Fx-006 study [16].
In the tafamidis-tafamidis group, there were
no statistically significant differences in the
monthly rate of change in measures including
NIS-LL, Norfolk QOL-DN,
P
7 NTs, and
P
3 NTs
scores when comparing the first 18 months of
the previous study with the 12 months of the
extension study [16]. The monthly rate of
change of mBMI dropped in the tafamidis-
tafamidis group after entry into Fx-006, but
remained higher than those observed prior to
treatment. By comparing the rate of progression
of several outcomes in the placebo-tafamidis
group between the two phases of the study, a
significant reduction in the rate of neurologic
and neurophysiologic deterioration was
observed (NIS-LL monthly rate of change,
Fx-005: 0.34; Fx-006: 0.16; P = 0.01). The
deterioration attested by the Norfolk QOL-DN
score during Fx-005 was arrested in Fx-006 in
this group (monthly rate of change: -0.16;
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P\0.01) and there was a positive rate of change
of mBMI as opposed to a decline observed in
Fx-005 (-1.77; P\0.0001) [16].
To test the third hypothesis, the monthly
rate of change between the two patient
populations was compared over the period of
30 months in all efficacy measures. There were
significant treatment group (tafamidis-tafamidis
vs. placebo-tafamidis) differences in the mean
change from baseline Fx-005 at 30 months for
NIS-LL (3.0 points vs. 6.8 points; P = 0.04) and
for
P
7 NTs nds (1.6 vs. 4.4; P\0.01) [16]. No
statistically significant difference in the
monthly rate of change for Norfolk QOL-DN
and mBMI was noted at 30 months. The mBMI
reversed to a positive value for the
placebo-tafamidis group in the extension study
and might have accounted for this lack of
difference. TTR stabilization was achieved in
both treatment groups and was more than 90%.
No new safety or tolerability issues were
noticed. Taken together, the results indicated
that the beneficial effects of tafamidis were
sustained over a 30-month period and that
early-start treatment is desirable [16]. Long-term
data are expected from another open-label
extension study (see Fx1A-303, below).
Fx1A-201
In addition to the Fx-005 study, a parallel study
was conducted in patients with TTR-FAP due to
non-Val3OMet mutations to assess the effect of
tafamidis on TTR stabilization and clinical
outcomes in these variants [17]. Fx1A-201 was
a 12-month study that enrolled patients from
centers in Europe and the USA; the study had an
open-label design and was divided into two
parts. In the first part, patients who received a
daily dose of 20 mg of tafamidis were studied at
week 6 for TTR stabilization. In the second part,
those who demonstrated TTR stabilization were
followed for a total of 12 months. The main
exclusion criteria was the presence of Val3OMet
or Val122Ile TTR mutations. TTR stabilization
was studied using the same method as in the
previous studies [13, 16] and was considered a
primary outcome at week 6.
As secondary endpoints, TTR stabilization at
months 6 and 12 and the neurologic impairment
score (NIS)—which captures clinically
meaningful changes in neurological function
(e.g., sensation, muscle weakness, and reflexes)—
were used in this trial, but measures were taken
from both lower and upper limbs. The sum of 5
parameters of nerve conduction was used to
evaluate large-fiber function of peripheral
nerves. Norfolk QOL-DN and mBMI were also
used. As the group of non-Val3OMet patients
comprised of different phenotypical expressions,
troponin I and N-terminal prohormone of brain
natriuretic peptide (NT-proBNP) cardiac
biomarkers were used as outcomes. Several
echocardiographic parameters [i.e.,
left-ventricular (LV) wall thickness,
interventricular septal thickness, left-atrial
diameter, LV mass, LV ejection fraction, and
ratio of mitral peak velocity of early filling to
early diastolic mitral annular velocity] and
12-lead EKG were also recorded [17].
Of 21 patients enrolled, 18 completed the
trial [17]. The baseline demographics of patients
demonstrated that this group of non-Val30Met
patients had longer average disease duration
(mean 64.7 months) and were of a more
advanced age (mean 59.3 months) than the
Val30Met patients enrolled in the previous
studies. They demonstrated significant
neurological and functional impairment in
contrast with the early presentation of the
disease in the previous populations. In
addition, they represented a considerably
heterogeneous population in which eight
different TTR non-Val3OMet mutations were
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observed with mixed neurological and CM
presentation [17].
TTR stabilization at week 6 was achieved in 18
(94.7 %) of 19 of the ITT population (two
patients could not be evaluated) [17]. One
patient who did not present TTR stabilization
had a TTR Gly47Ala mutation; assessed again at
months 3 and 6, this patient then achieved
stabilization. After 12 months of treatment, the
mean increase in total NIS was 5.3 (NIS score
ranges from 0 to 240). Patients with higher
baseline NIS ([70) presented a greater increase
in NIS than patients with lower baseline scores. A
small increase of 0.2 in nerve conduction
summated score (
P
5 NCs nds) was observed
after 12 months and the results were similar
when excluding those who presented with
maximal abnormality in nerve function since
baseline [17].
Mean changes in Norfolk QOL-DN from
baseline at months 6 and 12 were negligible
[17]. The overall nutritional status was
maintained over 12 months with variation
between the 6-month and 12-month analyses.
In patients with an interventricular septal wall
[12 mm at baseline, no clinically significant
change was observed. Mean NT-proBNP values
were elevated at baseline and remained stable at
month 12. Troponin I was normal at baseline
and remained stable throughout. Patients that
were considered at a high risk of heart failure
at baseline, defined as levels of NT-proBNP
[1000 pg/ml, had a median increase in
NT-proBNP levels of 521 pg/ml as compared to
47 pg/ml in patients with a low likelihood of
heart failure at baseline. Adverse events were
mostly related to the severity of the disease.
Abnormalities in echocardiography and EKGs
were considered consistent with cardiac
morbidity [17]. Long-term data and controlled
trials on evaluating more specifically cardiac
function are expected.
Fx1A-303
Interim results were presented at the European
Federation of Neurological Societies (EFNS)
meeting in 2014 from the ongoing Fx1A-303
study [18]. Fx1A-303 is an open-label trial that
enrolled patients who either received tafamidis
in the single-treatment arm of the Fx1A-201
study (all non-Val30Met) [17], or completed the
18-month placebo-controlled Fx-005 trial [13]
and then received tafamidis in the 12-month
Fx-006 extension study (all Val30Met) [16].
Tafamidis was generally well tolerated [18].
All patient groups experienced some disease
progression; those with Val30Met in the
tafamidis-tafamidis arm had numerically
smaller increases in NIS-LL and Norfolk QOL-
DN scores than those in the placebo-tafamidis
arm at 66 months. Furthermore, once patients in
the placebo-tafamidis arm began treatment with
tafamidis, their apparent rate of increase in NIS-
LL scores was similar to those in the tafamidis-
tafamidis arm. Non-Val30Met patients had a
higher disease burden at baseline and increases
in NIS-LL scores at 48 months in a similar way to
those seen in the Val30Met patients at
66 months. Long-term use of tafamidis in
Val30Met patients was associated with less
advancement in polyneuropathy impairment;
however, the lack of a placebo control group
hampers the interpretation of the efficacy results
in non-Val30Met patients [18].
POST HOC ANALYSES
OF TAFAMIDIS
Impact of Tafamidis on Nutritional Status
In 2014, Suhr et al. [19] published a post hoc
analysis of a more detailed account of the
impact of tafamidis on nutritional status of
patients with TTR-FAP enrolled in clinical trials.
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mBMI was used as a physiological indicator for
treated patients as it is closely related to the
duration of gastrointestinal disturbances,
malabsorption, and survival after LT [19].
For previous trials, mBMI was calculated as
the product of the BMI and serum albumin
concentration [19]. Height, weight, and
albumin were measured during the baseline
visit, and weight and serum albumin were
measured every 6 months up to month 30.
The ITT population of 125 patients in the
randomized phase of the trial was reduced to
71 patients in the extension study due to
reasons previously described. Baseline
evaluation of both groups of patients
(tafamidis and placebo) showed that 70%
presented gastrointestinal symptoms but that
mean values of mBMI were normal as the
patient groups constituted of only early-stage
patients [19].
For the placebo-controlled phase of the trial,
placebo recipients experienced a worsening in
mBMI yielding a change from baseline to
month 18 of -33 ± 16 (P = 0.04; worsening of
1020 ± 244 kg/m2 by g/l at each visit) [19]. In
contrast, the recipients of tafamidis had a
change of mBMI from baseline at 18 month of
?37 ± 14 (P = 0.01; improvement of
1032 ± 167 kg/m2 by g/l at each visit),
representing a LS mean difference of
73 ± 21 kg/m2 by g/l between groups
(P = 0.001). In conclusion of the open-label
extension phase, placebo-treated patients had
a change of mBMI from baseline of
?28 ± 19 kg/m2 by g/l while tafamidis-treated
patients had a change of ?16 ± 18 kg/m2 by g/l.
The effect of the reduction in sample size during
the extension phase influenced the ability to
achieve statistical significance. These results
were consistently comparable across study
centers. The reversal of mean mBMI
decrements observed for the placebo-treated
patients during the open-label phase occurred
because of improvements in both components
of the index (BMI and albumin) [19].
A second analysis performed was the effect of
initial BMI on changes in BMI from baseline
[19]. Patients were divided into three groups:
Underweight (BMI\20 kg/m2), normal (BMI
20–25 kg/m2), and overweight (BMI[25 kg/
m2). Tafamidis-treated patients who were
underweight gained in BMI at 18 months
(1.5 ± 0.6 kg/m2), normal-weight patients
gained less (0.5 ± 0.3 kg/m2), and overweight
patients had a decrease in BMI (-0.5 ± 0.4 kg/
m2). For patients treated with the placebo, BMI
remained constant in the three groups with a
tendency for increased loss in overweight
patients [19].
In the open-label extension phase, the
tafamidis-tafamidis group at month 30
presented moderate increases in BMI for
underweight (0.6 ± 0.9 kg/m2) and
normal-weight (0.5 ± 0.4 kg/m2) patients,
while the overweight group showed moderate
decreases (-0.4 ± 0.6 kg/m2) [19]. The patients
in the placebo-tafamidis group who were
underweight remained stable. The normal
group showed a moderate increase in BMI
(0.8 ± 0.6 kg/m2), whereas overweight patients
showed a small decrease in BMI (-0.1 ± 0.5 kg/
m2). The main finding was the improvement in
or maintenance of nutritional status associated
with tafamidis use. Interestingly, BMI increase
associated with tafamidis was largely confined
to those with relatively low values at baseline in
whom improvement is desired as opposed to
overweight patients [19].
Tafamidis and Management of the Cardiac
Aspects of TTR-FAP
Another post hoc analysis addressed the QT
interval of the EKG study [20] in healthy
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volunteers to assess the potential for QTc
interval prolongation during tafamidis
treatment at supra-therapeutic doses (400 mg
single dose). The purpose of the study was the
potential use of tafamidis in CM. The study
demonstrated that administration of tafamidis
400 mg in a single daily dose did not prolong
QTc [20].
Fx1B-201
Results were recently published for the phase II,
open-label Fx1B-201 study [21] in which
TTR-CM patients received 20 mg once daily of
tafamidis. Tafamidis was used for 12 months
together with the routine standard of care.
Thirty-one WT-CM patients and 4 TTR
V122I-CM patients were included. The mean
age of patients was 76 years and their mean
disease duration was 8 years. Ninety-four
percent of patients had mild to moderate
cardiac dysfunction (class I or II of NYHA
classification). Kaplan–Meier analysis of
survival from time of diagnosis was 87.5%
survival rate at 30 months. Overall, 5.7%
subjects died, 25.7% experienced at least one
cardiovascular-related hospitalization, and
25.7% experienced the composite endpoint of
death or cardiovascular-related hospitalization.
Cardiac biomarkers were elevated at baseline and
increased over 12 months while troponin I and T
remained relatively stable in the WT population.
NYHA classification and 6-min walk test
functional assessments supported the previous
results. NYHA was improved or preserved for
75% of patients after 12 months and the overall
population demonstrated minimal changes in
the 6-min walk test (mean change from baseline
of -11 m). Thirty of 31 patients (96.8%)
achieved TTR stabilization after 6 weeks, and
25/28 patients (89.3%) after 12 months [21].
This is in contrast with a previous study on a
prospective evaluation of the morbidity and
mortality of WT and V122I-mutant TTR
amyloid CM: The Transthyretin Amyloidosis
Cardiac Study (TRACS; mean change from
baseline in 6-min walk test of -44 m) [22].
The above studies in part provided the basis
for the rationale to evaluate tafamidis for the
treatment of TTR-CM. The ATTR-ACT trial [24]
is an ongoing phase III, randomized study of
tafamidis versus placebo for the treatment of
TTR-CM [23].
REAL-WORLD CLINICAL
EXPERIENCE
France was the first country to approve
tafamidis for the treatment for patients with
stage 1 TTR-FAP to slow disease progression in
September 2011. According to Adams et al. [24,
25], tafamidis is an option for early-stage
symptomatic TTR-FAP with positive amyloid
biopsy. Treatment should be initiated and
monitored by an experienced medical doctor.
At each 6-month assessment, a complete
multisystem approach is used and decisions
are made as whether to pursue with tafamidis or
to choose another option, including LT.
Remaining on the waiting list for LT in the
meanwhile is presented as an option. Decisions
to change treatment are based on an increase in
disease stage (1–3; Coutinho et al. [26]), an
increase of one point in polyneuropathy
disability (PND) score, an increase in one
point for NYHA, conduction abnormalities on
an EKG, or the presence of impotence and
orthostatic hypotension [24, 25].
Lozeron et al. [27] studied the effect of
tafamidis in predominantly late-onset
Val30Met TTR-FAP patients in a prospective,
non-randomized-controlled trial carried out at
one of the French national reference centers.
Thirty-seven patients were enrolled between
December 2009 and July 2011 and assessed by
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NIS and disability scores. During the first
6 months of treatment, the mean progression
of NIS-LL score was similar to that observed
during the period before treatment. During the
first year, 55% of patients deteriorated with
respect to disability and 38% with respect to
NIS. The authors concluded that, in most
advanced Val30Met TTR-FAP, tafamidis was
not able to stop disease progression with
respect to NIS and disability [27].
In late-onset cases, a different composition
of amyloid deposit has been shown in most
tissues, especially in the heart, as opposed to
early-onset cases. In work by Koike et al. [28],
amyloid deposits were examined postmortem in
eight cases. In early-onset cases, deposits were
highly congophilic and had long, parallel fibrils
in most organs. In late-onset cases, deposits
were generally weakly congophilic and had
short, haphazard fibrils, mostly like deposits
from native TTR and similar to that observed in
senile systemic amyloidosis (SSA), suggesting a
different mechanism for organ damage. In
addition, the amount of amyloid deposition in
the peripheral nervous system was small for the
severity of nerve fiber loss in late-onset cases, as
was shown in another postmortem study from
the same authors [29], precluding a mechanism
of damage that goes beyond the deposit itself
and should be taken into consideration if we are
to put the effects of tafamidis into late-onset
cases into the right context.
Authors, including Ueda and Ando [30] and
Sekijima [31], have also considered tafamidis as
a treatment option for patients with TTR-FAP
since its approval by the Japanese
Pharmaceuticals and Medical Devices Agency
in 2013 for TTR-FAP (any stage). Nevertheless,
Ueda and Ando [30] highlight the need to
follow long-term outcomes, cardiac functions,
and ophthalmic symptoms in patients treated
with tafamidis.
Obici and Merlini [32], in their review of
treatment options for TTR-FAP, indicate
tafamidis as a treatment option for patients
with stage 1 TTR-FAP of Coutinho [26], PND
BII. In those patients, liver or combined
liver–heart transplantation is often approached
as a second-line option when disease
progression has occurred while on tafamidis
treatment. Consistently, participation into a
placebo-controlled trial is often considered
only after inadequate response to tafamidis.
Barbosa da Silva et al. [33] compared the
disease progression of early-stage Val3OMet
TTR-FAP patients treated with tafamidis or
submitted to LT with that of untreated
patients from two referral centers—CEPARM,
Rio de Janeiro, Brazil and Henri-Mondor, Paris,
France—included in the Transthyretin
Amyloidosis Outcome Survey (THAOS)
database. The main inclusion criteria were: the
presence of Val3OMet TTR mutation; a biopsy
positive for amyloid deposit; a PND score of I or
II; treatment or nontreatment after 2007 (the
date inclusion into the THAOS database was
commenced); and at least two independent
medical evaluations within a minimum of
1 year (maximum 4 years). The assessment
methods used were NIS (any increase [2
points was considered deterioration), and
Karnofsky and PND scores (any increase was
considered deterioration). Twenty-two patients
were selected, of whom 13 were Brazilian and 9
were French, and were divided into three
distinct groups: 8 patients submitted to LT, 7
using tafamidis, and 7 who were not treated. Of
them 77.27% were in PND stage I and 22.73%
were in stage II. The median evaluation period
of patients submitted to LT was 3 (range
1–5) years, treated with tafamidis was 3 (range
2–5) years, and with no treatment was 2.5
(range 1–4) years. The three groups had similar
demographic and clinical profiles, based on age,
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disease severity, the duration of disease, and the
period of treatment. Gender was distributed
equally between the groups [33].
NIS scores showed no deterioration in 42.9%
of the tafamidis-treated group, as opposed to
25% in LT group and 14.9% in the no-treatment
group [33]. Karnofsky score showed no
deterioration in 42.86% of patients treated
with tafamidis, 75% of the LT group, and
14.29% of the no-treatment group. According
to PND scores, patients treated with tafamidis
and LT indicated no deterioration in PND,
85.72% and 87.5%, respectively, against
28.57% of the no-treatment group.
Considering the restraints of the study (with a
small population and retrospective analysis), it
was the first to compare LT to tafamidis
treatment between comparable groups of
patients. After a follow-up of 2–6 years in this
small population study, similar neurological
outcomes were observed in the tafamidis-
treated and LT groups when compared to the
untreated group, using the Karnofsky and PND
scores as an evaluation method. Both had a
better clinical course in relation to the natural
evolution of the disease [33]. Controlled
prospective studies comparing both treatments
would be very useful but also very difficult to
achieve.
Coelho et al. [34], from the two most
important reference centers in Portugal (Porto
and Lisboa), presented their 1-year efficacy and
safety experience of treatment with tafamidis.
Overall, 122 patients were evaluated at baseline
and then every 6 months through a
comprehensive protocol that included NIS
score, BMI, Norfolk QOL-DN score, and renal,
thyroid and liver function tests. Adverse events
were also recorded. Patients were classified as
responders if NIS changes across 12 months were
\2, according to Dyck’s classification. BMI, liver,
renal and thyroid function tests remained stable
after 1-year of follow-up. Norfolk QOL-DN score
improved from baseline to 1 year (3.21 vs. 2.89,
respectively, P\0.01). Mean NIS changed from
baseline to 6 months (2.45 vs. 2.51, respectively,
P\0.01) and stabilized between 6 and
12 months (2.51 vs. 2.54, respectively,
P\0.01), showing a delay in the stabilization
effect as occurred in the main trials. Patients that
were classified as responders (n = 75. 61 %)
showed a significant decrease in NIS score
between 6 and 12 months (2.41 vs. 2.33,
respectively, P\0.01) [32]. Tafamidis prevented
neurological, BMI, and QOL deterioration in
61 % of the cases treated for one year.
FUTURE DIRECTIONS
Experts and patients are currently awaiting the
long-term results obtained so far from treatment
with tafamidis, as well as it safety profile, so that
these can be comparable to the results of LT, of
which we have a long experience of more than
20 years to demonstrate its efficacy [3, 35]. Also
to be noted is that the mortality and morbidity
associated with LT and subsequent
immunosuppression, as well as the availability
of organs and the well-documented continuous
deposition of amyloid in tissues (mainly in the
heart) coming from native TTR after LT, support
the need for an alternative option to LT.
The recent publication from Maia et al. [36]
indicates that central nervous system (CNS)
clinical involvement occurs in Val30Met
TTR-FAP patients regardless of LT. Long-term
CNS involvement was monitored in 87
consecutive Val30Met TTR-FAP and 35
non-TTR-FAP LT patients investigated with
computed tomography scan,
electroencephalography, and extensive
neurovascular workup. Focal neurological
episodes occurred in 31% (27/87) of Val30Met
TTR-FAP patients and in 5.7% (2/35) of the
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non-TTR-FAP LT patients. CNS TTR-FAP
progressed from the meninges and its vessels
toward meningocortical vessels and the
superficial brain parenchyma, as disease
duration increased. Longer disease duration
after LT can provide the necessary time for
TTR-FAP to progress [36]. Another limitation of
LT is that if the age of a patient is greater than
65 years then this usually constitutes an
exclusion criterium in most centers, thus
making tafamidis a good safe alternative for
late-onset cases [37].
The impact of tafamidis on cardiac disease is
also of great interest as little is known about its
long-term effect. Cardiac data previously arose
from the Fx1A-201 trial [17], although recently
published data from the Fx1B-201 study [21], is
encouraging further evaluation of tafamidis for
TTR-CM in an ongoing worldwide phase III
double-blind, randomized, placebo-controlled
study of tafamidis in up to 400 patients with
TTR-CM (NCT01994889) [23]. The efficacy of
tafamidis for SSA will be partially determined
after the conclusion of this trial. As tafamidis is
a safe drug and equally capable of stabilizing
mutant and native TTR, interest is increasing for
this potential treatment for a senile population.
In addition, there is no knowledge regarding
the impact of tafamidis on renal disease, which
would have a very important, positive effect on
long-term survival of patients with ATTR.
According to the results of trials and
real-world experience [13, 16–21, 23–25, 27,
30–35], the use of tafamidis in very early
symptomatic/asymptomatic TTR-FAP patients,
before the overt onset of the disease, would
benefit most from its effect on disease
progression—the most important goal at the
present moment. To achieve this, medical
doctors and patient communities are fostering
searches for early disease markers, carriers of the
mutation in families, and final diagnosis of
suspected and non-suspected cases (late-onset
and sporadic cases for instance).
To foster the increase in the ability to
recognize new patients and carriers, it is
crucial to spread the knowledge of the disease
and make diagnostic tools available. In
developed countries, local networks of medical
doctors work well. Referral centers act by
centralizing data and preceptorship. In
underdeveloped countries, the challenge is far
more difficult as teaching about a rare disease
faces poor health systems and the complete lack
of diagnostic means, in an unfavorable social
and economic environment. In past years,
countries like those in Latin America are
slowly recognizing the presence of TTR–FAP
with various presentations and multiple genetic
backgrounds and the interest in this extremely
underdiagnosed disease is definitely increasing.
Late-onset and sporadic cases are very
challenging to diagnose but the availability of
new tools for diagnosis and the increase in the
awareness of this disease are enhancing our
capability of detecting those cases very
frequently misdiagnosed as idiopathic or
chronic inflammatory demyelinating
polyneuropathy, to mention just a few. Their
recognition will enable a much earlier initiation
of therapy than is the usual case and hence
improve the prognosis after treatment [38].
Another question of interest is the effect of
tafamidis on preventing the development of
amyloidosis in the recipient of a domino LT, as
well as its use as a combined treatment with LT.
There is awareness of some patients being
treated in these contexts but so far no results
have been reported.
A randomized clinical trial was reported in
2013 where diflunisal was shown to reduce the
rate of progression of neurologic impairment
and to preserve patient QOL at the 2-year
follow-up period of the study [39]. This study
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included both Val30Met TTR-FAP and
non-Val30Met TTR-FAP patients and therefore
cases with phenotypical variety including both
early and late onset. The safety profile was
considered satisfactory. Several patients are
using diflunisal in real-world practice although
it is not yet available in several parts of the
world thus limiting the gain of experience. A
long-term report looking at both the
maintenance of the beneficial effect of
diflunisal and mostly its satisfactory safety
profile is still awaited, especially as it is an
anti-inflammatory drug that would be used for a
long period or for a lifetime in a group of
patients experiencing CM and renal disfunction
with relatively high frequency [39]. This will
help the physician in care of the patient to
decide which TTR stabilizer to use.
At least two important and promising
clinical trials with agents capable of reducing
TTR production, either by RNAi-targeting
messenger, RNA transcribed from TTR gene
[40], or by anti-sense oligonucleotide drugs
designed to target human TTR mRNA, are
enrolling FAP/FAP-CM patients. The capacity
of both novel drugs to suppress TTR protein
levels with a mean reduction of around 75% at
the chosen doses determined in previous phase
I/II trials [40] is unquestionable. To determine
their efficacy composite endpoints including
neurological, neurophysiological, nutritional,
autonomic, and cardiac aspects will be used.
In the future, patients and experts will certainly
have different treatment options, either alone
or in combination, depending on the
presentation or stage of the disease.
CONCLUSION
Tafamidis has opened the way for a nonsurgical
treatment possibility for TTR-FAP, being both
safe and efficacious in treating early-stage
patients, and a practical oral drug to be
prescribed for a lifetime. In the future,
tafamidis will potentially find a more
important use as a drug capable of delaying or
arresting TTR-FAP expression as much as
possible; however, this will be dependent on
its proper use at the correct moment, that is,
especially before the overt expression of
TTR-FAP. The last task will be the more
challenging to achieve unless a robust
biomarker for TTR-FAP onset is identified.
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